In the study, not only the number of CD4+ and CD8+ T cells significantly increased, but also the gene expression associated with type 1 T-cell recruitment and functionality enhanced when AXL is inhibited in R428-treated tumor-bearing mice (43). This evidence concerns the gene CD8A and neoplasm.